D. Gandara

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

Leena Gandhi, D. Ross Camidge, Moacyr Oliveira et al. · Journal of Clinical Oncology · 2011 · 591 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics

Laurent Claret, Jin Y. Jin, Charles Ferté et al. · Clinical Cancer Research · 2018 · 72 citations

Medicine, Oncology, Pharmacology +17

S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results

Katherine M.W. Pisters, Eric Vallières, Paul Bunn et al. · Journal of Clinical Oncology · 2005 · 61 citations

Medicine, Oncology, Surgery +17

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

Melinda M. Mortenson, Michael G. Schlieman, Subbulakshmi Virudachalam et al. · Lung Cancer · 2005 · 56 citations

Medicine, Oncology, Pharmacology +15

Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study

Timothy W. Synold, Chris H. Takimoto, James H. Doroshow et al. · Clinical Cancer Research · 2007 · 48 citations

Pharmacy, Oncology, Pharmacology +17